Home About us Editorial board Ahead of print Browse Articles Search Submit article Instructions Subscribe Contacts Login 
  • Users Online: 85
  • Home
  • Print this page
  • Email this page

Previous article Browse articles Next article 
J Res Med Sci 2017,  22:131

Severe mitral regurgitation, an unusual manifestation of chemotherapy-induced cardiotoxicity

1 Department of Cardiology, Najafabad Branch, Islamic Azad University, Isfahan, Iran
2 Department of Nephrology, Isfahan Kidney Diseases Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
3 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

Date of Submission17-Jun-2017
Date of Decision09-Aug-2017
Date of Acceptance23-Sep-2017
Date of Web Publication26-Dec-2017

Correspondence Address:
Dr. Mohaddeseh Behjati
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jrms.JRMS_471_17

Rights and Permissions

Cardiotoxicity is one of the most feared side effects of chemotherapy with enhanced morbidity and mortality in survivors. Arrhythmia, heart failure, myocardial ischemia, hypertension, and thromboembolism are commonly reported as side effects. Hereby, we are reporting a case of severe mitral regurgitation as a complication of chemotherapy.

Keywords: Cardiotoxicity, chemotherapy, mitral regurgitation

How to cite this article:
Mirdamadi A, Naeini AE, Behjati M. Severe mitral regurgitation, an unusual manifestation of chemotherapy-induced cardiotoxicity. J Res Med Sci 2017;22:131

How to cite this URL:
Mirdamadi A, Naeini AE, Behjati M. Severe mitral regurgitation, an unusual manifestation of chemotherapy-induced cardiotoxicity. J Res Med Sci [serial online] 2017 [cited 2020 Oct 26];22:131. Available from: https://www.jmsjournal.net/text.asp?2017/22/1/131/221515

  Introduction Top

Cardiotoxic side effects related to chemotherapy limit dosing and impose cancer survivor to enhanced morbidity and mortality.[1] Current established guidelines for screening of chemotherapy-related cardiotoxicity are mainly based on a serial assessment of the left ventricular ejection fraction.[2] Cardiac tissue is damaged by variety of ways during cancer treatment.[3] The speculated mechanism of valvular regurgitation could be secondary to chemotherapy-induced reduced ejection fraction, but insufficient data favors this mechanism as the whole. Degenerative valvular regurgitation disproportionate to decrease in the left ventricular ejection fraction and valvular or myocardial damage should be considered in survivors of chemotherapy survivors.[4]

  Case Report Top

Our case was a 48-year-old woman who underwent chemotherapy for treatment of invasive ductal carcinoma of the breast. She was under close observation of cardiologist from the beginning of therapy. Her chemotherapy started by Adriamycin and Cyclophosphamide. After 4 courses of this therapy, 4 courses of combination therapy by Pertuzumab/Trastuzumab and Taxotel started. Combination therapy followed by surgery and then radiotherapy. Pathologic examination of removed tissue specimen revealed no residual malignant cell, but she faced myocardial dysfunction during chemotherapy. Furthermore, she suffered from severe mitral regurgitation during her therapy. Precise evaluation of mitral valve showed no obvious cause for this severe mitral regurgitation and severe mitral regurgitation was not secondary to left ventricular dilation or mitral valve annulus dilation. Aggravation of mitral regurgitation was so obvious that lead to consideration for its management. The patient was evaluated for mitral valve repair or mitral valve clip. In the worst period of heart injury, left ventricular ejection fraction decreased to 30%–35%. In this state, chemotherapy was discontinued. Medical therapy that had initiated from the first days of chemotherapy, increased and aggressive medical treatment for heart failure continued. In the peak time of myocardial dysfunction, left ventricular end diastolic volume was 130ml. After several months of dilemma for how to approach mitral regurgitation, cardiac condition started to recovery. Mitral regurgitation improved much better than cardiac contraction during a year after that. Finally, mitral regurgitation severity decreased to mild degree and left ventricular end diastolic volume decreased to 80ml. Two-dimensional(2D) and 3D echocardiography images before and after recovery are depicted in [Figure 1] and [Figure 2], respectively.
Figure1: Severe mitral regurgitation and increased left ventricle volumes induced by chemotherapy

Click here to view
Figure2: Decreased severity of mitral regurgitation and decreased left ventricle volumes after cessation of chemotherapy

Click here to view

  Discussions Top

Hereby, we presented a case of severe mitral regurgitation during chemotherapy which improved significantly by cessation of chemotherapy, in addition to appropriate cardiac treatment. Severe mitral regurgitation is a yet unreported manifestation of chemotherapy-induced cardiotoxicity which needs prompt attention. Fortunately, mitral regurgitation was reversible similar to left ventricular dysfunction, and we did not need an interventional and invasive strategy to manage it. Since each chemotherapy agent has an impact on cardiovascular system, cardio-oncology knowledge should be joined from the beginning of patient management.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understand that name and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

McGowanJV, ChungR, MaulikA, PiotrowskaI, WalkerJM, YellonDM, etal. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 2017;31:63-75.  Back to cited text no. 1
JijiRS, KramerCM, SalernoM. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. JNucl Cardiol 2012;19:377-88.  Back to cited text no. 2
EwerM, BenjaminR, YehE. Cardiac complications of cancer treatment. In: KufeDW, PollockRE, WeichselbaumRR, WeichselbaumR, BastR, GanslerT, etal., editors. Holland-Frei Cancer Medicine. 6thed. Hamilton, ON: BC Decker; 2003.  Back to cited text no. 3
MurbraechK, WethalT, SmelandKB, HolteH, LogeJH, HolteE, etal. Valvular dysfunction in lymphoma survivors treated with autologous stem cell transplantation: ANational cross-sectional study. JACC Cardiovasc Imaging 2016;9:230-9.  Back to cited text no. 4


  [Figure 1], [Figure 2]


Previous article  Next article
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
Case Report
Article Figures

 Article Access Statistics
    PDF Downloaded178    
    Comments [Add]    

Recommend this journal